Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Implantica AG
  6. News
  7. Summary
    IMP A SDB   SE0014855029

IMPLANTICA AG

(IMP A SDB)
  Report
Delayed Nasdaq Stockholm  -  11:29 2022-09-30 am EDT
41.10 SEK   +1.23%
08/23Implantica AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
05/11Implantica AG Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
03/07Implantica Ag Announces Launch of Refluxstop™ in Uk
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Implantica AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2021

02/18/2022 | 02:00am EDT

Implantica AG reported earnings results for the fourth quarter ended December 31, 2021. For the fourth quarter, the company reported sales was EUR 0.107 million compared to EUR 0.026 million a year ago. Net loss was EUR 6.25 million compared to EUR 3.15 million a year ago.


© S&P Capital IQ 2022
All news about IMPLANTICA AG
08/23Implantica AG Reports Earnings Results for the Second Quarter and Six Months Ended June..
CI
05/11Implantica AG Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
03/07Implantica Ag Announces Launch of Refluxstop™ in Uk
CI
02/21Implantica AG Announces Filing of Comprehensive eHealth Patent Applications for Its Pla..
CI
02/18Implantica AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
CI
02/18Implantica AG Reports Earnings Results for the Full Year Ended December 31, 2021
CI
02/01Implantica Appoints New COO
MT
02/01Implantica AG Appoints Paul Meadas as Chief Operating Officer
CI
2021Implantica Successfully Performs Cadaver Implantations of Pipeline Products and Several..
CI
2021Implantica AG Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
More news
Financials
Sales 2022 1,87 M 1,83 M 1,83 M
Net income 2022 -24,0 M -23,5 M -23,5 M
Net cash 2022 54,9 M 53,8 M 53,8 M
P/E ratio 2022 -9,14x
Yield 2022 -
Capitalization 1 069 M 1 048 M 1 048 M
EV / Sales 2022 543x
EV / Sales 2023 76,5x
Nbr of Employees 29
Free-Float 4,86%
Chart IMPLANTICA AG
Duration : Period :
Implantica AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMPLANTICA AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 3,77 €
Average target price 9,82 €
Spread / Average Target 160%
EPS Revisions
Managers and Directors
Peter Forsell Chief Executive Officer
Andreas Öhrnberg Chief Financial Officer
Liselott Kilaas Chairman
Paul Mead Chief Operating Officer
Johan Bojs Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
IMPLANTICA AG-36.77%1 048
SHOCKWAVE MEDICAL, INC.55.93%9 990
NOVOCURE LIMITED1.20%7 958
MASIMO CORPORATION-51.79%7 415
PENUMBRA, INC.-34.01%7 184
GETINGE AB-51.48%4 702